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Table 1
Variable Pre-PTRAS Post-PTRAS p
SP 153.0417.07 124.7511.40 <0.001
Men 146.9215.88 124.089.00 <0.001
Women 158.3316.76 125.3313.43 <0.001
DP 92.5010.76 77.548.23 <0.001monitoring and no serious arrhythmia was detected. The mean scores of the domains
of the SF-36 namely, physical functioning, role functioning, social functioning, mental
health, vitality, pain and general health were similar in ASD patients and the control
group (Table 1). The only sociodemographic variable that was found to be associated
with quality of life outcome parameters in the patient group was educational level.
Higher educational level was signiﬁcantly associated with better mental health and
better general health perception (r¼0.248, p¼0.04; r¼0.315, p¼0.008, respectively).
Conclusıon: Adult patients who underwent percutaneous ASD closure perceive their
quality of life as good as their healty counterparts.Table 1
ASD patiens Control group p value
Physical
functioning
73.820.7 73.927.3 0.97
Role physical 67.441.2 69.240.2 0.79
Pain 64.325.5 61.725.6 0.55
General health 60.525.3 62.320.8 0.64
Vitality 56.321.2 55.220.9 0.76
Social functioning 74.922.9 73.322.8 0.69
Role emotional 63.639.9 62.241.9 0.84
Mental health 63.719.0 63.617.5 0.96
The SF-36 domain scores in ASD patients and the control group.
Men 87.318.81 76.317.93 0.001
Women 97.0010.49 78.608.60 <0.001
Number of drug 3.710.85 2.460.69 <0.001
Men 3.850.80 2.310.75 <0.001
Women 3.600.91 2.600.63 0.006
Creatinine 1.130.31 1.130.31 0.150
Men 1.410.53 1.170.32 0.088
Women 1.150.42 1.100.30 0.767
eGFR 60.8935.21 61.7521.08 0.899
Men 62.7731.31 70.6922.94 0.300
Women 59.2739.30 54.0016.37 0.632
Table 2: Pre-Percutaneous transluminal renal angioplasty with stent (PTRAS) and at 6 month
follow up results of blood pressure, medications, creatinine and estimated glomerular ﬁltra-
tion rate. Abbrevations: PTRAS, percutaneous transluminal renal artery stenting; SP, systolic
blood pressure; DP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate.
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Background and AIM: Metabolic syndrome (MS) is associated with cardiovascular
mortality and morbidity in patients with acute coronary syndrome. The purpose of this
studywas to evaluate the impact ofMSon long-termclinical outcomes in patientswithpure
non-ST segment myocardial infarction (NSTEMI) or unstable angina pectoris (USAP).
Methods-Results: We prospectively enrolled 310 consecutive NSTEMI/USAP patients
(74 females;meanage, 59.311.9years).The studypopulationwasdivided into twogroups:
MS(+) and MS(-). The clinical outcomes of the patients were followed for up to 3 years.
Increased 3-year cardiovascular mortality and reinfarction were observed in the
MS(+) group, as compared to theMS(-) group (15 vs. 3.4%, p¼0.001, and 22.2 vs. 8.3%,
p¼0.001, respectively). Hospitalization rates for heart failure and stroke were not
signiﬁcantly different between the two groups on follow-up. By a Cox multivariate
analysis, a signiﬁcant association was noted between MS and the adjusted risk of 3-year
cardiovascular mortality (odds ratio 3.4, 95% conﬁdence interval, 1.24-9.1, p¼0.02).
Conclusıon: These results suggest that MS is associated with an increased risk of 3-
year cardiovascular mortality and reinfarction in patients with NSTEMI/USAP.
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Objectıves: Atherosclerotic renal artery stenosis (ARAS) is associated with uncon-
trolled hypertension and chronic renal failure. The aim of this study is to evaluate the
inﬂuence of gender and presence of chronic renal failure on the outcomes of percu-
taneous transluminal renal artery stenting (PTRAS) due atherosclerosis.
Methods: A total of 28 ARAS patients underwent PTRAS and 36 stents were placed.
Basal characteristics, laboratory data and blood pressure of patients were recorded.
The differences between genders and improvement/deterioration of renal functions
and blood pressure were analyzed. The predictors of outcomes were determined.
Results: Baseline characteristics were similar between men and women. Signiﬁcant
improvement of systolic and diastolic blood pressure control was achieved after
PTRAS (153.0417.07 mmHg vs. 124.7511.40 mmHg, p¼0.001 and 92.5010.76
mmHg vs. 77.548.23 mmHg, p<0.001, respectively) (Table-1). Although mean
estimated glomerular ﬁltration rate (eGFR) and creatinine levels did not signiﬁcantly
improved at 6 month follow up visit in compared to baseline values, of the 28 patients
13 (46.4%) patients had improvement of renal functions.
Conclusıon: Our results suggests that PTRAS is a safe procedure and may offer blood
pressure control but beneﬁcial effects of PTRAS on renal function may be anticipated
in selected group of patients, especially those with a low eGFR.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTPP-359
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Background: Metoprolol, carvedilol and nebivolol were different beta blockers with
different properties. In the literature there are various studies evaluating renal effects
of these beta blockers under different conditions. However, to the best of our
knowledge there is not any study comparing preventive effects of these three beta
blockers with each other against contrast induced nephropathy (CIN).
Aım: We aimed to investigate and compare the probable prophylactic effects of three
beta blocker agents, carvedilol, nebivalol and metoprolol against CIN.
Method: 184 patients who were hospitalized for further evaluation with coronary
angiography and have been using beta blocker agent (50 mg metoprolol, 25 mg
carvedilol or 5 mg nebivolol) at least for a week were enrolled to the study. Exclusion
criteria included dialysis patients, recent exposure to contrastmedia or a nephrotoxic
agent within 7 days before the study, urgent percutaneous coronary intervention (PCI),
requiring loop diuretics, theophylline/ aminophylline, dopamine throughout the study,
hemodynamically unstable patients. Patients were divided into three groups: meto-
prolol (M) (64 patient), nebivolol (N) (60 patient), carvedilol (C) (60 patient). All
groups were hydrated before and after the coronary procedure for 12 hours with the
rate of 1 ml/kg/hour intravenous isotonic saline. Serum cretainine (Cr) levels were
checked in the second and ﬁfth days of the study. The primary end point was the
occurence of CIN. We deﬁned CIN as an increase 0.5 mg/dL and/or 25% in serum
creatinine (SCr) concentration at day 2 and/or day 5 of the procedure.
Results: The distribution of various characteristics of the participants is shown in
Table 1and Table 2. Seven (10.9%) patients in group M developed CIN, as did 5
patients (8.3%) in group N and 2 patients (3.3%) in group C. Patients in carvedilol
group developed less CIN, however the difference with the group C and the others
did not reach statistical signiﬁcance (p¼0.283) (Figure 1). Changes in mean Cr
level from baseline to day 2 and day 5 were not statistically signiﬁcant in all groups.
Conclusıon: If there is indication for a beta blocker therapy before the coronary
angiography procedure, although the comperative results with metoprolol and nebi-
volol did not reach statistical signiﬁcance, this study demonstrated a weak evidence
favouring against carvedilol prescription as it would be a better choice for the
prevention of CIN.ERS C223
